Non-small cell lung cancer squamous · 6 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Carboplatin and Gemcitabine (GCb) and Durvalumab N/A - protocol | — | R 268 186 | 28d | — | — | — | — | — |
Cisplatin and Gemcitabine (GC) and Durvalumab Variant #01 | — | R 266 494 | 28d | — | ~12.9 mo | — | — | 3 |
Carboplatin and Paclitaxel (CP) and Durvalumab Variant #01 | — | R 232 277 | 28d | ~10.2 mo | — | ~12 | ~R 2 787 323 PFS proxy · indirect | 1 |
Cisplatin and Gemcitabine (GC) and Pembrolizumab Variant #01 | — | R 85 180 | 21d | — | — | — | — | 1 |
Carboplatin and Paclitaxel (CP) and Nivolumab Variant #01 Partial | — | R 2 239 | 21d | — | — | — | — | 1 |
Cisplatin and Docetaxel (DC) and Nivolumab Variant #01 Partial | — | R 2 031 | 21d | — | — | — | — | 1 |
6 of 6 regimens shown